ESMO 2026总结：全球验证到来

At ESMO 2026, the most important message for China biopharma was not any single dataset but the emergence of global clinical validation, as multiple practice-changing readouts (TroFuse-005, Saffron, Clarity-gastric01, etc.) demonstrated successful China-to-global data translation. Kelun-Biotech's sac-TMT was the most clinically validated asset in coverage: in 1L PD-L1-negative nsq-NSCLC (OptiTROP-Lung06), sac-TMT plus Keytruda achieved mPFS of 15.0 months versus 5.7 months for Keytruda plus chemo (PFS HR 0.49; p<0.0001) with an OS HR of 0.58, and it claimed the first global Ph3 win in late-line endometrial cancer;